Laparoscopic Bariatric Surgery: Two Regimens of Venous Thromboprophylaxis: Prospective Randomized Study
NCT ID: NCT02128178
Last Updated: 2015-04-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE1/PHASE2
700 participants
INTERVENTIONAL
2013-11-30
2016-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Anti Xa Levels Under Two Different Regimens of Enoxaparin VTE Prophylaxis After Sleeve Gastrectomy for Morbid Obesity
NCT01970202
Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Bariatric Surgery
NCT06689241
Thromboprophylaxis and Bariatric Surgery
NCT00444652
Low Molecular Weight Heparin vs Direct Oral Anticoagulant After Bariatric Surgery
NCT06913595
Fondaparinux Population Pharmacokinetic to Morbid Obese Patients in Post-operatory Bariatric Surgery
NCT01064596
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
ENOXAPARIN 2 HOURS BEFORE
Giving 40 mg enoxaparin SQ 2 hours before surgery and daily for 10 days thereafter
Enoxaparin 40 mg 2 hours before arm
Enoxaparin 40 mg 2 hours before surgery
Enoxaparin 40 mg 12 hours before arm
Enoxaparin 40 mg 12 hours before surgery
Enoxaparin 40 mg 12 hours before
Enoxaparin 40 mg 12 hours before surgery and once daily for 10 days thereafter
Enoxaparin 40 mg 2 hours before arm
Enoxaparin 40 mg 2 hours before surgery
Enoxaparin 40 mg 12 hours before arm
Enoxaparin 40 mg 12 hours before surgery
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Enoxaparin 40 mg 2 hours before arm
Enoxaparin 40 mg 2 hours before surgery
Enoxaparin 40 mg 12 hours before arm
Enoxaparin 40 mg 12 hours before surgery
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mansoura University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
MOHAMED ABDELLATIF
phd
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
mohamed e abd ellatif, phd
Role: PRINCIPAL_INVESTIGATOR
Mansoura University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Manoura University
Al Mansurah, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Amaral FC, Baptista-Silva JC, Nakano LC, Flumignan RL. Pharmacological interventions for preventing venous thromboembolism in people undergoing bariatric surgery. Cochrane Database Syst Rev. 2022 Nov 22;11(11):CD013683. doi: 10.1002/14651858.CD013683.pub2.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Enoxaparin
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.